Imaging-based Biomarkers as Predictors of Response to Anti-VEGF Therapy in Idiopathic Choroidal Neovascularization
- PMID: 39006934
- PMCID: PMC11238929
- DOI: 10.4103/meajo.meajo_173_21
Imaging-based Biomarkers as Predictors of Response to Anti-VEGF Therapy in Idiopathic Choroidal Neovascularization
Abstract
Purpose: The purpose of this study was to identify biomarkers that predict the response of treatment-naive idiopathic choroidal neovascularization (iCNV) to anti-VEGF treatment.
Methods: Fourteen eyes diagnosed with iCNV underwent a dilated fundus examination, Swept Source Optical Coherence Tomography (SS-OCT) and Optical Coherence Tomography - Angiography (OCT-A), and were given an anti-VEGF injection. The same examinations were repeated at every follow-up visit. Analysis of the pre- and posttreatment images was done to identify possible biomarkers which were evaluated to check association with decreased need for multiple anti-VEGF injections.
Results: At presentation, 11 patients showed a compact pattern, while three patients showed an arborizing pattern on OCT angiography (P = 1). On follow-up imaging, seven patients showed a marked response, five patients showed a moderate response, and two patients showed a mild response to anti-VEGF injection. Among the seven patients showing a marked response, only one required a repeat injection (P = 0.03). On analysis of SS-OCT, a novel Retinal Pigment Epithelium (RPE) healing response was observed in posttreatment imaging of six patients (P = 0.59).
Conclusion: A "marked" response to the first anti-VEGF injection results in a more sustained response and is a positive prognostic factor. RPE healing response is an interesting observation that merits further evaluation. Morphology of neovascular membranes has no effect on long-term need for multiple anti-VEGF injections.
Keywords: Anti-VEGF; OCT; OCT-A; biomarkers; idiopathic choroidal neovascularization.
Copyright: © 2024 Middle East African Journal of Ophthalmology.
Conflict of interest statement
There are no conflicts of interest.
Figures


Similar articles
-
Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization.BMC Ophthalmol. 2020 Mar 19;20(1):115. doi: 10.1186/s12886-020-01390-4. BMC Ophthalmol. 2020. PMID: 32192468 Free PMC article.
-
Exploring the Ability of Novel Choroidal Biomarkers in Predicting Treatment Outcomes of Polypoidal Choroidal Vasculopathy.Ophthalmic Res. 2024;67(1):573-583. doi: 10.1159/000541572. Epub 2024 Sep 23. Ophthalmic Res. 2024. PMID: 39312893
-
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.Retina. 2017 Oct;37(10):1873-1879. doi: 10.1097/IAE.0000000000001447. Retina. 2017. PMID: 28079756
-
Anti-VEGF Treatment for Secondary Neovascularization in Pseudoxanthoma Elasticum - Age of Onset, Treatment Frequency, and Visual Outcome.Am J Ophthalmol. 2024 Sep;265:127-136. doi: 10.1016/j.ajo.2024.03.026. Epub 2024 Apr 12. Am J Ophthalmol. 2024. PMID: 38614195
-
Inflammatory choroidal neovascularization: An evidence-based update.Surv Ophthalmol. 2025 May-Jun;70(3):451-466. doi: 10.1016/j.survophthal.2024.12.004. Epub 2024 Dec 18. Surv Ophthalmol. 2025. PMID: 39706532 Review.
References
-
- Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241–4. - PubMed
-
- Kang HM, Koh HJ. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. Am J Ophthalmol. 2013;155:713–9. 719.e1. - PubMed
-
- Shi X, Wei W, Zhang C. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: A comparative study on visual acuity, retinal and choroidal thickness. Chin Med J (Engl) 2014;127:2279–85. - PubMed
-
- Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Long-term outcome and recurrence of idiopathic choroidal neovascularization treated with intravitreal bevacizumab. J Ocul Pharmacol Ther. 2016;32:431–6. - PubMed
-
- Zhou P, Yang L, Jin X. Ranibizumab versus bevacizumab for the treatment of idiopathic choroidal neovascularization:2-year results. Eur J Ophthalmol. 2016;26:262–7. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources